Earnings Call · Q1 FY2023·2023-05-16

Q1 23EPS -14.29%·Rev n/aQ4 22EPS -10.34%·Rev n/aQ3 22EPS 0.00%·Rev n/aQ2 22EPS -10.00%·Rev n/a⚠ consensus missing

NRX Pharmaceuticals, Inc. NRXP

Suzanne Messere — Chief Financial Officer

Stephen Willard — Chief Executive Officer

Seth Van Voorhees — Chief Financial Officer

+5.3%1d on move date+4.0% vs SPY3d+11.5%5d+2.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NRXP calls or request research access.

More NRXP calls Browse calls Request research access